Exclusive Summary

• **Independent IP & FTO**: Backed by a proprietary mRNA platform with over 270 patent applications, offering partners 'Freedom to Operate' by breaking global patent barriers in LNP and mRNA synthesis.
• **AI-Driven Innovation**: Utilizes AI-assisted protein/mRNA design and proprietary delivery systems (LNP & Non-LNP) to enhance stability and translation efficiency, positioning it as a potential Best-in-Class asset.
• **Validated Platform & CMC**: The underlying technology is validated by CDE approvals for other pipeline assets (RSV/Shingles), supported by in-house GMP pilot plants that ensure cost-effective manufacturing and rapid clinical supply.

Asset Materials

Contact Us for Full Materials